Simple hysterectomy non-inferior to radical hysterectomy for pelvic recurrence in women with low-risk cervical cancer: NEJM Medha Baranwal29 Feb 2024 6:45 PM ISTCanada: A recent study published in the New England Journal of Medicine compared simple versus radical hysterectomy in women with low-risk cervical...
Bayer gets USFDA Breakthrough Therapy designation for BAY 2927088 for non-small cell lung cancer harboring HER2 activating mutations Ruchika Sharma29 Feb 2024 1:30 PM ISTBAY 2927088 was derived from Bayer's long-standing strategic research alliance with the Broad Institute of MIT and Harvard in Cambridge, MA, USA.
Risk-reducing mastectomy may lower breast cancer mortality, finds study Dr. Kamal Kant Kohli28 Feb 2024 8:00 PM ISTA study co-led by Professor Kelly Metcalfe of the Lawrence Bloomberg Faculty of Nursing, and researchers at the Familial Breast Cancer Research Unit...
Annual breast cancer screening beginning at 40 saves lives Dr. Kamal Kant Kohli28 Feb 2024 1:45 AM ISTAnnual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the highest reduction in mortality with minimal risks,...
Merck gets positive EMA Committee opinion for Keytruda, chemotherapy combo for Resectable non-small cell lung cancer Ruchika Sharma26 Feb 2024 2:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced that the European Medicines Agency's Committee for Medicinal...
Bristol Myers Squibb, Immunocore Holdings ink pact to evaluate IMC-F106C, nivolumab combo in registrational Phase 3 first-line advanced cutaneous melanoma trial Ruchika Sharma25 Feb 2024 2:00 PM ISTOxfordshire: Immunocore Holdings plc, a commercial-stage biotechnology company has announced that it has entered into a clinical trial...
FDA approves Amtagavi for treatment of Advanced melanoma Dr. Kamal Kant Kohli22 Feb 2024 7:00 PM ISTThe US Food and Drug Administration has approved first cellular therapy Amtagavi for treatment of Advanced melanoma. It is one-time cell therapy for...
USFDA accepts for priority review Bristol Myers Squibb application for Krazati, cetuximab combo for colorectal cancer Ruchika Sharma22 Feb 2024 1:30 PM ISTNew York: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental...
Merck application for Keytruda plus chemotherapy for Primary Advanced or Recurrent Endometrial Carcinoma accepted by USFDA for priority review Ruchika Sharma22 Feb 2024 12:30 PM ISTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for...
JnJ gets USFDA nod for Bi-weekly dose of blood cancer therapy Tecvayli Ruchika Sharma21 Feb 2024 11:39 AM ISTUnited States: The U.S. Food and Drug Administration has approved a bi-weekly dose of Johnson & Johnson's blood cancer therapy Tecvayli, the...
New research offers hope to those affected by aggressive brain cancer Anshika Mishra20 Feb 2024 9:15 AM ISTNew research from the University of Sussex holds promise for extending life expectancy and enhancing treatment options for a common and aggressive...
Taxane-based chemotherapy in Asian breast cancer patients tied to skin changes, hair loss: Study Medha Baranwal20 Feb 2024 7:00 AM ISTSouth Korea: A recent study published in The Journal of Dermatology evaluated the effects of treatment regimens in Asian breast cancer (BC)...
